• Profile
Close

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): A phase 3, placebo-controlled, randomized trial

The Lancet Sep 06, 2019

Bhatt DL, Steg PG, Mehta SR, et al. - Through a phase 3 randomized, double-blinded, placebo-controlled trial, done across 1,315 sites in 42 countries, experts examined whether stable patients with coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI) would benefit from treatment with aspirin plus ticagrelor. Ticagrelor added to aspirin decreased cardiovascular death, myocardial infarction, and stroke—but with increased major bleeding in patients with diabetes, stable coronary artery disease, and prior PCI. Overall, ticagrelor offered a favorable net clinical advantage (more than in patients without a history of PCI). This influence explicates that long-term therapy with ticagrelor along with aspirin should be considered in patients with diabetes and a history of PCI who have endured antiplatelet therapy, have high ischemic risk, and low bleeding risk.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay